Angion Biomedica expands staff with new Director of Chemistry and Director of Clinical Operations (PDF)
Angion Biomedica Corp. in-licenses aldosterone synthase inhibitors from ElexoPharm GmbH, complementing its ongoing program in chronic kidney Disease (PDF)
Since 1998 Angion has been developing treatments for major organ diseases.
One in 10 American adults, more than 20 million, has some level of chronic kidney disease.
Angion is testing new treatments to reduce or prevent kidney injury.